Evidence map›Paper›PMID 40881173›Full record

ArticleFrontiers in genetics2025

A comprehensive analysis identifies and validates NPC1 as a potential biomarker for prognosis in HCC.

Xingjun Lu, Tianyao Gou, Xuxing He, Xia Chen, Daqing Yang, Xiaozhen Peng

Abstract read
In one paragraph

Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xingjun Lu *College of Laboratory Medicine, Hunan University of Medicine, Huaihua, China.
Tianyao Gou *Xiangya Second Hospital, Central South University, Changsha, China.
Xuxing He *Clinical Medicine Department, Xinjiang Medical University, Urumqi, China.
Xia ChenDepartment of Neurology, The First Affiliated Hospital of Hunan University of Medicine, Huaihua, China.
Daqing YangCollege of Laboratory Medicine, Hunan University of Medicine, Huaihua, China.
Xiaozhen PengCollege of Laboratory Medicine, Hunan University of Medicine, Huaihua, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Niemann-Pick type C1 protein (NPC1), a key regulator of intracellular cholesterol transport and a transmembrane protein, has been implicated in carcinogenesis, particularly in hepatocellular carcinoma (HCC). Despite the noted association, the specific role of NPC1 in HCC remains underexplored. In this study, we conducted a comprehensive analysis of NPC1 expression across diverse gene expression databases to elucidate its prognostic significance and functional interactions. Utilizing LinkedOmics for co-expression network analysis and KEGG for functional enrichment, we identified a set of genes co-expressed with NPC1 and its associated biological pathways. Our findings demonstrate that NPC1 is frequently upregulated and amplified in HCC tumor tissues, with higher expression levels significantly associated with reduced overall survival (OS), progression-free survival (RFS), and disease-free survival (DFS). Functional enrichment analysis of the top 50 positively correlated genes with NPC1 highlighted significant enrichment in pathways related to organelle fission, nuclear division, chromosomal region spindle formation, and centrosome function, suggesting a role for NPC1 in DNA replication processes. These findings establish a correlation between NPC1 expression and HCC prognosis, laying the groundwork for future studies to explore the therapeutic potential of NPC1 inhibition in HCC.

Indexed as

biomarkerHCCNPC1prognosistherapeutic target

Identifiers

PMID40881173
PMCPMC12380838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.